The purpose of this study was to optimize and characterize novel polymeric mixed micelles loaded with 2,5,9,11-tetramethyl-5H-indolo-[2,3-b]quinoline, a compound bearing the highest antitumor activity in 5H series derivatives of indoloquinolines and 5,11-dimethyl-5H-indolo-[2,3-b]quinoline which displayed a strong antibacterial, antimycotic and cytotoxic activity in vitro against leukemia P388 and L1210 and melanoma B16.

Mixed polymeric micelles were prepared by thin-film hydration method in several proportions in order to confirm optimal value of variables i.e. polymers mass fraction and concentration, amount of derivative of a indoloquinoline, amount of water and level of hydration temperature. Mixed polymeric micelles proved higher sizes and lower polydispersity than micelles prepared from only one of these Pluronics. The determined drug-loading coefficients (DL%), encapsulation ratios (ER%) and Zeta potential values allow to assume that the particles have proper size and density to remain in suspension which leads to repulse. Such combination ensures that the solution or dispersion resists aggregation.

This observation gives a strong ground to claim that mixed polymeric micelles may be considered as an effective nanocarrying system for 2,5,9,11-tetramethyl-5H-indolo-[2,3-b]quinoline and 5,11-dimethyl-5H-indolo-[2,3-b]quinoline.

• Legal notice:
  

  Copyright (c) Pielaszek Research, all rights reserved.
  The above materials, including auxiliary resources, are subject to Publisher's copyright and the Author(s) intellectual rights. Without limiting Author(s) rights under respective Copyright Transfer Agreement, no part of the above documents may be reproduced without the express written permission of Pielaszek Research, the Publisher. Express permission from the Author(s) is required to use the above materials for academic purposes, such as lectures or scientific presentations.
  In every case, proper references including Author(s) name(s) and URL of this webpage: https://science24.com/paper/28077 must be provided.

1. Ethical and generic drugs
2. Ebselen analogues: synthesis and antimicrobial activity
3. The comparison of the stability indicating  two HPLC methods and their application for the determination of bosentan in coated tablets 
4. Influence of the side chain on the cytotoxicity of betulin derivatives
5. Synthesis of new 5H-indolo[2,3-b]quinoline derivatives with a high selective cytotoxic activity
6. Improved manufacturing process of bosentan monohydrate.
7. Assessment of selected synthesis of bosentan towards elimination of known impurities.
8. New cyclic dermorphin analogues containing a carbonyl bridge
9. Investigation of unknown impurities in cyclic dermorphin analogue by HPLC-MS
10. Efficient preparation of a key intermediate in the exemestane synthesis
11. Physicochemical characterization of sunitinib and its impurities
12. Synthesis and biological evaluation of new amino acid and dipeptide derivatives of neocryptolepine as anticancer agents. 
13. Determination of reaction progress in synthesis of EE-3 by NMR technique
14. Optimization of BR-8 synthesis
15. The synthesis of ezetimibe with high stereochemical purity
16. New amino acid and peptide derivatives of 5H-indolo[2,3-b]quinoline and their biological activity.
17. The cytotoxic activity of glycosides of indolo[2,3-b]quinoline derivatives.
18. Disubstituted indolo[2,3-b]quinoline derivatives - the cytotoxic activity in vitro against various human tumor cell lines.
19. Mono substituted 5H- and 6H-indolo[2,3-b]quinoline derivatives and their ability to overcome the barrier of drug resistance.
20. Searching for lead molecules as potential new CNS agents in the serotonin 5-HT₆ screening assay
21. New amino acid derivatives of 6H-indolo[2,3-b]quinolines
22. THE CYTOTOXIC GLYCOSIDES OF INDOLO[2,3-B]QUINOLINE DERIVATIVES. IN VITRO AND IN VIVO STUDIES
23. MONO SUBSTITUTED 5H-INDOLO[2,3-B]- QUINOLINE DERIVATIVES AND THEIR ABILITY TO OVERCOME THE BARRIER OF DRUG RESISTANCE.
24. DISUBSTITUTED INDOLO[2,3-b]QUINOLINE DERIVATIVES. THE CYTOTOXIC ACTIVITY IN VITRO AGAINST VARIOUS HUMAN TUMOR CELL LINE.